0.1043 USD
-0.02 (-17.94%)
0.0805 USD
-0.02 (-22.82%)
SYRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. SYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SYRA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- SYRA had negative earnings in the past year.
- SYRA had a negative operating cash flow in the past year.
- SYRA had negative earnings in each of the past 5 years.
- SYRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- SYRA's Return On Assets of -102.17% is on the low side compared to the rest of the industry. SYRA is outperformed by 94.29% of its industry peers.
- Looking at the Return On Equity, with a value of -130.59%, SYRA is doing worse than 80.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.17% | ||
| ROE | -130.59% | ||
| ROIC | N/A |
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SYRA has a Gross Margin (20.71%) which is comparable to the rest of the industry.
- SYRA's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for SYRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SYRA has more shares outstanding
- The debt/assets ratio for SYRA is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -2.79, we must say that SYRA is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -2.79, SYRA is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.05 indicates that SYRA is not too dependend on debt financing.
- SYRA has a better Debt to Equity ratio (0.05) than 78.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.79 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
- SYRA has a Current Ratio of 5.46. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
- SYRA's Current ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
- A Quick Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
- SYRA has a Quick ratio of 5.46. This is amongst the best in the industry. SYRA outperforms 95.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.46 | ||
| Quick Ratio | 5.46 |
3. Growth
3.1 Past
- SYRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.98%.
- Looking at the last year, SYRA shows a very strong growth in Revenue. The Revenue has grown by 44.67%.
- SYRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.22% yearly.
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SYRA. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- SYRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYRA HEALTH CORP - CLASS A / SYRA FAQ
What is the ChartMill fundamental rating of SYRA HEALTH CORP - CLASS A (SYRA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SYRA.
Can you provide the valuation status for SYRA HEALTH CORP - CLASS A?
ChartMill assigns a valuation rating of 0 / 10 to SYRA HEALTH CORP - CLASS A (SYRA). This can be considered as Overvalued.
How profitable is SYRA HEALTH CORP - CLASS A (SYRA) stock?
SYRA HEALTH CORP - CLASS A (SYRA) has a profitability rating of 0 / 10.
How financially healthy is SYRA HEALTH CORP - CLASS A?
The financial health rating of SYRA HEALTH CORP - CLASS A (SYRA) is 4 / 10.